Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ASP-1929 photoimmunotherapy vs physician's choice in recurrent HNSCC
jRCT2071200060Phase 3Recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing ASP-1929 photoimmunotherapy with Physician's choice standard-of-care (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started May 2019; status: recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2071200060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200060.